|Systematic (IUPAC) name|
|Bioavailability||Close to 100%|
|Biological half-life||1.5 hours|
|CAS Registry Number|
|Molecular mass||250.333 g/mol|
|Melting point||61 to 63 °C (142 to 145 °F)|
Gemfibrozil is the generic name for an oral drug used to lower lipid levels. It belongs to a group of drugs known as fibrates. It is most commonly sold as the brand name, Lopid. Other brand names include Jezil and Gen-Fibro.
- Development history 1
- Actions 2
- Therapeutic effects 3
- Nontherapeutic effects and toxicities 4
- Indications 5
- Contraindications and precautions 6
- Drug interactions 7
- Environmental data 8
- References 9
- External links 10
Gemfibrozil was selected from a series of related compounds synthesized in the laboratories of the American company Parke Davis in the late 1970s. It came from research for compounds that lower plasma lipid levels in humans and in animals.
- Is an activator of peroxisome proliferator-activated receptor-alpha (PPARα), a nuclear receptor that is involved in metabolism of carbohydrates and fats, as well as adipose tissue differentiation. This increase in the synthesis of lipoprotein lipase thereby increases the clearance of triglycerides.
- Reduce triglyceride levels 
- Reduce very low density lipoprotein (VLDL) levels
- Modest reduction of low density lipoprotein (LDL) levels
- Moderate increase in high density lipoprotein (HDL) levels
Nontherapeutic effects and toxicities
- GI distress
- Musculoskeletal pain
- Increased incidence of gallstone
- Hypokalemia (low blood potassium)
- Increased risk of cancer
- Hyperlipidemia (Type III): Gemfibrozil is the drug of choice for therapy.
- Hypertriglyceridemia (Type IV): Gemfibrozil, though not as effective as niacin, is better tolerated.
Contraindications and precautions
Gemfibrozil should not be given to these patients:
- Hepatic dysfunction
Gemfibrozil should be used with caution in these higher risk categories:
- Biliary tract disease
- Renal dysfunction
- Pregnant women
- Obese patients
- Anticoagulants: Gemfibrozil potentiates the action of warfarin and indanedione anticoagulants.
- Statin drugs: Concomitant administration of fibrates (including gemfibrozil) with statin drugs increases the risk of muscle cramping, myopathy, and rhabdomyolysis.
Gemfibrozil has been detected in biosolids (the solids remaining after wastewater treatment) at concentrations up to 2650 ng/g wet weight. This indicates that it survives the wastewater treatment process.
- Rodney, G; et al. (1976). "The Hypolipidemic Effect of Gemfibrozil (CI-719) in Laboratory Animals". Proc. roy. Soc. Med. 69 (Supplement 2): 6–9.
- "Gemfibrozil." WebMD.com Accessed 14 June 2014. http://www.webmd.com/drugs/drug-11423-gemfibrozil+oral.aspx
- DrugBank Gemfibrozil
- NIH Gemfibrozil Drug Info
- Lopid International Study
- Author (2004). "Safety of Statins". Circulation 109: III–50–III–57.